The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125716031 12571603 1 I 201502 20160707 20160719 20160719 EXP CA-HQ SPECIALTY-CA-2016INT000568 INTERCHEM 32.00 YR F Y 0.00000 20160719 CN CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125716031 12571603 1 PS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Oral 20 MG,1 IN 1 W 201749 20 MG TABLET
125716031 12571603 2 SS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Oral 20 MG,1 IN 1 W 201749 20 MG TABLET
125716031 12571603 3 SS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Oral 20 MG,1 IN 1 W 201749 20 MG TABLET
125716031 12571603 4 SS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Oral 20 MG,1 IN 1 W 201749 20 MG TABLET
125716031 12571603 5 SS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Oral 20 MG,1 IN 1 W 201749 20 MG TABLET
125716031 12571603 6 SS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Subcutaneous 3.5714 MG (25 MG,1 IN 1 W) 201749 25 MG TABLET
125716031 12571603 7 SS METHOTREXATE SODIUM. METHOTREXATE SODIUM 1 Subcutaneous 3.5714 MG (25 MG,1 IN 1 W) 201749 25 MG TABLET
125716031 12571603 8 SS XELJANZ TOFACITINIB CITRATE 1 Oral 10 MG (5 MG,2 IN 1 D) Y 0 10 MG
125716031 12571603 9 SS ACTEMRA TOCILIZUMAB 1 UNK Y 0
125716031 12571603 10 SS HUMIRA ADALIMUMAB 1 UNK 0
125716031 12571603 11 SS LEFLUNOMIDE. LEFLUNOMIDE 1 20 MG (20 MG,1 IN 1 D) 0 20 MG
125716031 12571603 12 SS SULFASALAZINE. SULFASALAZINE 1 500 MG AND UP TO 1 G TWICE A DAY 0 500 MG
125716031 12571603 13 SS TOFACITINIB CITRATE TOFACITINIB CITRATE 1 UNK Y 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125716031 12571603 1 Rheumatoid arthritis
125716031 12571603 8 Rheumatoid arthritis
125716031 12571603 9 Rheumatoid arthritis
125716031 12571603 10 Rheumatoid arthritis
125716031 12571603 11 Rheumatoid arthritis
125716031 12571603 12 Rheumatoid arthritis
125716031 12571603 13 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
125716031 12571603 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
125716031 12571603 Activities of daily living impaired
125716031 12571603 Drug ineffective
125716031 12571603 Insomnia
125716031 12571603 Migraine
125716031 12571603 Osteoporosis
125716031 12571603 Postoperative wound infection
125716031 12571603 Rheumatoid arthritis
125716031 12571603 Upper limb fracture

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125716031 12571603 1 20120412 0
125716031 12571603 2 20130509 0
125716031 12571603 3 20130808 0
125716031 12571603 4 20150415 0
125716031 12571603 5 20150617 0
125716031 12571603 6 200308 0
125716031 12571603 7 20140910 0
125716031 12571603 8 20150109 2015 0
125716031 12571603 9 2010 2015 0
125716031 12571603 10 2005 2010 0
125716031 12571603 11 200408 200409 0
125716031 12571603 12 200003 200308 0
125716031 12571603 13 20150414 20150617 0